arrow
K

Kim Papp

Temerty Faculty of Medicine
H指数:106
被引数:4.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pharmacokinetics and safety of candidate biosimilar CT-P55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, Phase I study

CT-P55候选生物类似药与参比药secukinumab的药代动力学和安全性:一项三臂、随机、双盲、单剂量、多中心、I期研究

2026-02-220
PRE
Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summary

使用0.15%罗氟司特乳膏长期治疗≥6岁特应性皮炎患者(INTEGUMENT-OLE临床研究):一份通俗语言摘要

2026-01-010
PRE
Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary

罗氟司特泡沫与赋形剂泡沫治疗脂溢性皮炎(STRATUM临床研究):一份简明语言摘要

2026-01-010
PRE
Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study

ruxolitinib乳膏在白癜风中的随机,双盲治疗退出或继续: 来自TRuE-V长期扩展3期研究的结果

2025-12-260
OAAI
361 Lebrikizumab Dosed Every 8 Weeks as Maintenance Provides Long-Lasting Response in Patients with Moderate-to-Severe Atopic Dermatitis

361 勒布rikizumab 每8周作为维持剂量使用可为中重度特应性皮炎患者提供长效应答

2025-11-100
PRE
Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III Trials

0.3%罗氟司特乳膏在慢性斑块状银屑病患者中的研究:DERMIS III期试验合并的PASI和PASI-HD结果

2025-10-240
OA
Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study

纳莫利zumab治疗特应性皮炎长达2年的开放标签扩展研究的安全性与有效性

2025-10-130
OAAI
Safety and Efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the Phase 2 STRIDE study

envudeucitinib(一种高度选择性、口服异位TYK2抑制剂)在患有中重度斑块状银屑病患者中的安全性与有效性:Phase 2 STRIDE研究52周开放标签扩展期结果

2025-10-060
OAAI
SPECTREM phase IIIb clinical trial results through week 16: guselkumab efficacy and safety for the treatment of low body surface area, moderate psoriasis with high-impact site involvement

SPECTREM IIIb期临床 trial 结果(16周):guselkumab 治疗低体表面积、中度银屑病伴高影响部位受累的疗效与安全性

2025-10-011
OAAI
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials

鲁安克zumab治疗活动性银屑病关节炎的疗效与安全性:KEEpsAKE 1和KEEpsAKE 2随机临床试验196周结果

2025-09-300
OA
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials

每日一次口服icotrokinra与安慰剂及每日一次口服deucravacitinib对比,用于中重度斑块状银屑病患者的两项Ⅲ期、随机、安慰剂对照和活性对照药对照试验(ICONIC-ADVANCE 1 & 2)

2025-09-180
PRE
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks

乌帕替尼(Upadacitinib)治疗中重度特应性皮炎的疗效与安全性:第3期随机临床试验结果(为期140周)

2025-09-030
OAAI